Larson Financial Group LLC Cuts Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Larson Financial Group LLC cut its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 21.8% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,351 shares of the biopharmaceutical company’s stock after selling 654 shares during the quarter. Larson Financial Group LLC’s holdings in Catalyst Pharmaceuticals were worth $49,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of CPRX. Assetmark Inc. raised its holdings in Catalyst Pharmaceuticals by 2.4% in the 3rd quarter. Assetmark Inc. now owns 72,245 shares of the biopharmaceutical company’s stock worth $1,436,000 after acquiring an additional 1,704 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in shares of Catalyst Pharmaceuticals by 159.2% in the third quarter. Los Angeles Capital Management LLC now owns 200,282 shares of the biopharmaceutical company’s stock worth $3,982,000 after purchasing an additional 123,020 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Catalyst Pharmaceuticals in the third quarter worth $625,000. Victory Capital Management Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 5.8% during the third quarter. Victory Capital Management Inc. now owns 291,505 shares of the biopharmaceutical company’s stock valued at $5,795,000 after purchasing an additional 15,996 shares in the last quarter. Finally, Natixis Advisors LLC boosted its position in shares of Catalyst Pharmaceuticals by 37.7% during the third quarter. Natixis Advisors LLC now owns 45,637 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 12,491 shares during the last quarter. 79.22% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on CPRX. Robert W. Baird lifted their price target on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, March 3rd. Baird R W raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. HC Wainwright reissued a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 28th. Finally, Bank of America reiterated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $32.50.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Gary Ingenito sold 44,904 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the transaction, the insider now owns 68,873 shares of the company’s stock, valued at approximately $1,521,404.57. The trade was a 39.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now owns 188,564 shares of the company’s stock, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Trading Up 1.1 %

Shares of NASDAQ CPRX opened at $21.20 on Thursday. The stock has a market capitalization of $2.57 billion, a price-to-earnings ratio of 17.97, a P/E/G ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.47 and a 12-month high of $24.64. The firm’s 50-day moving average price is $22.27 and its 200-day moving average price is $21.52.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.